Sonoma Story

<div class='circular--portrait' style='background:#FF0000;color: #F5FFFA;font-size:4em;'>SP</div>
SNOA -- USA Stock  

USD 8.43  0.10  1.20%

Sonoma Pharmaceuticals is scheduled to announce its earnings tomorrow. As many retail investors are getting excited about healthcare space, it is fair to go over Sonoma Pharmaceuticals outlook under the current economic conditions. What exactly are Sonoma Pharmaceuticals shareholders getting in December?
Published over a month ago
View all stories for Sonoma Pharmaceuticals | View All Stories
Should you trust Sonoma Pharmaceuticals (NASDAQ:SNOA) current analyst consensus?
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Sonoma Pharmaceuticals has an asset utilization ratio of 153.95 percent. This suggests that the company is making $1.54 for each dollar of assets. An increasing asset utilization means that Sonoma Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.
What is the right price you would pay to acquire a share of Sonoma Pharmaceuticals? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.

What is happening with Sonoma Pharmaceuticals this year

Annual and quarterly reports issued by Sonoma Pharmaceuticals are formal financial statements that are published yearly and quarterly and sent to Sonoma stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934. Companies such as Sonoma Pharmaceuticals often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How Sonoma utilizes its cash?

To perform a cash flow analysis of Sonoma Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Sonoma Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Sonoma Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Acquisition by Bruce Thornton of 27777 shares of Sonoma Pharmaceuticals subject to Rule 16b-3

Legal trades by Sonoma Pharmaceuticals insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Sonoma insider trading alert for grant of stock option (right to buy) by Bruce Thornton, COO, on 13th of January 2021. This event was filed by Sonoma Pharmaceuticals In with SEC on 2021-01-13. Statement of changes in beneficial ownership - SEC Form 4. Bruce Thornton currently serves as executive vice president - international operations and sales of Sonoma Pharmaceuticals [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is Sonoma a risky opportunity?

Let's check the volatility. Sonoma is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Sonoma (NASDAQ:SNOA) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. taking in a share of a Sonoma Pharmaceuticals stock makes you a part-owner of that company.

Sonoma Pharmaceuticals Current Consensus

Here is the current trade recommendation based on an ongoing consensus estimate among financial analysis covering Sonoma Pharmaceuticals. The Sonoma consensus assessment is calculated by taking the average estimates from all of the analysts covering Sonoma Pharmaceuticals

Strong Buy
2
Strong Buy2100.0
Buy00.0
Hold00.0
Sell00.0
Strong Sell00.0

Sonoma may start a bounce back in December

Current maximum drawdown is at 27.34. Sonoma Pharmaceuticals exhibits very low volatility with skewness of 0.82 and kurtosis of 3.49. However, we advise investors to further study Sonoma Pharmaceuticals technical indicators to make sure all market info is available and is reliable.

The Bottom Line

When is the right time to buy or sell Sonoma Pharmaceuticals? Buying stocks such as Sonoma Pharmaceuticals isn't very hard. However, what challenging for most investors is doing it at the right time. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities, deliver winning trades and diversify portfolios on a daily bases. On the whole, as of the 27th of November 2020, our concluding 30 days Buy-Hold-Sell recommendation on the company is Strong Sell. However, we believe Sonoma Pharmaceuticals is currently undervalued with very high odds of distress for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Sonoma Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com